Clinical trial
Duodenal Recellularization Via Electroporation Therapy for Suboptimally Controlled Type II Diabetes Mellitus and Steatotic Liver Disease (DRESS-1 Study)
NCT07390422 is registered in ClinicalTrials.gov with Chinese University of Hong Kong as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Duodenal Recellularization Via Electroporation Therapy for Suboptimally Controlled Type II Diabetes Mellitus and Steatotic Liver Disease (DRESS-1 Study)
- Lead sponsor
- Chinese University of Hong Kong
- Phase
- Not applicable
- Overall status
- Recruiting
- Start date
- September 1, 2026
- Completion date
- August 30, 2033
- Enrollment
- 40 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
masld - metabolic dysfunction-associated steatotic liver disease, metabolic syndrome (mets), t2dm (type 2 diabetes mellitus)